La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

GSK Gestione

Gestione criteri di controllo 1/4

GSK's Il CEO è Emma Walmsley, nominato in Apr2017, e ha un mandato di 7.33 anni. la retribuzione annua totale è £ 12.72M, composta da 10.3% di stipendio e 89.7% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 0.04% delle azioni della società, per un valore di £ 26.03M. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 5.7 anni e 2.9 anni.

Informazioni chiave

Emma Walmsley

Amministratore delegato

UK£12.7m

Compenso totale

Percentuale dello stipendio del CEO	10.3%
Mandato del CEO	7.3yrs
Proprietà del CEO	0.04%
Durata media del management	5.7yrs
Durata media del Consiglio di amministrazione	2.9yrs

Aggiornamenti recenti sulla gestione

We Think Shareholders Are Less Likely To Approve A Large Pay Rise For GSK plc's (LON:GSK) CEO For Now

May 02

Recent updates

GSK (LON:GSK) Is Paying Out A Dividend Of £0.15

Aug 05

GSK (LON:GSK) Will Pay A Dividend Of £0.15

May 05

We Think Shareholders Are Less Likely To Approve A Large Pay Rise For GSK plc's (LON:GSK) CEO For Now

May 02

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Emma Walmsley rispetto agli utili di GSK?
Data	Compenso totale	Stipendio	Guadagni aziendali
Jun 30 2024	n/a	n/a	UK£4b
Mar 31 2024	n/a	n/a	UK£4b
Dec 31 2023	UK£13m	UK£1m	UK£5b
Sep 30 2023	n/a	n/a	UK£6b
Jun 30 2023	n/a	n/a	UK£5b
Mar 31 2023	n/a	n/a	UK£4b
Dec 31 2022	UK£8m	UK£1m	UK£4b
Sep 30 2022	n/a	n/a	UK£3b
Jun 30 2022	n/a	n/a	UK£4b
Mar 31 2022	n/a	n/a	UK£4b
Dec 31 2021	UK£8m	UK£1m	UK£3b
Sep 30 2021	n/a	n/a	UK£4b
Jun 30 2021	n/a	n/a	UK£4b
Mar 31 2021	n/a	n/a	UK£5b
Dec 31 2020	UK£7m	UK£1m	UK£5b
Sep 30 2020	n/a	n/a	UK£6b
Jun 30 2020	n/a	n/a	UK£7b
Mar 31 2020	n/a	n/a	UK£5b
Dec 31 2019	UK£8m	UK£1m	UK£5b
Sep 30 2019	n/a	n/a	UK£5b
Jun 30 2019	n/a	n/a	UK£4b
Mar 31 2019	n/a	n/a	UK£4b
Dec 31 2018	UK£6m	UK£1m	UK£4b
Sep 30 2018	n/a	n/a	UK£2b
Jun 30 2018	n/a	n/a	UK£2b
Mar 31 2018	n/a	n/a	UK£1b
Dec 31 2017	UK£5m	UK£965k	UK£2b

Compensazione vs Mercato: La retribuzione totale di Emma ($USD 16.52M ) è superiore alla media delle aziende di dimensioni simili nel mercato UK ($USD 5.83M ).

Compensazione vs guadagni: La retribuzione di Emma è aumentata di oltre il 20%, mentre gli utili aziendali sono diminuiti di oltre il 20% nell'ultimo anno.

AMMINISTRATORE DELEGATO

Emma Walmsley (55 yo)

7.3yrs

Mandato

UK£12,718,000

Compensazione

Dame Emma N. Walmsley serves as an Independent Director of Microsoft Corp. since December 4, 2019. She serves as Chief Executive Officer of GlaxoSmithKline Plc since April 1, 2017. Dame Walmsley served as...

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Emma Walmsley	CEO & Director	7.3yrs	UK£12.72m	0.040% £ 25.9m
Julie Brown	CFO & Executive Director	1.3yrs	UK£5.14m	0.0024% £ 1.6m
Shobie Ramakrishnan	Chief Digital & Technology Officer	3.6yrs	Nessun dato	Nessun dato
Tony Wood	Chief Scientific Officer and Head of R&D	2yrs	Nessun dato	Nessun dato
Sarah Elton-Farr	Head of Investor Relations	no data	Nessun dato	Nessun dato
James Ford	Senior VP & Group General Counsel of Legal & Compliance	6yrs	Nessun dato	Nessun dato
Sally Jackson	Senior Vice President of Global Communications & CEO Office	5.4yrs	Nessun dato	Nessun dato
David Redfern	President of Corporate Development	no data	Nessun dato	Nessun dato
Diana Conrad	Chief People Officer	5.3yrs	Nessun dato	Nessun dato
Philip Thomson	President of Global Affairs	7.3yrs	Nessun dato	0.0057% £ 3.7m
Luke Miels	Chief Commercial Officer	6.9yrs	Nessun dato	Nessun dato
Kevin Sin	Senior VP & Head of Worldwide Business Development for Pharmaceuticals Research Development	6.2yrs	Nessun dato	Nessun dato

5.7yrs

Durata media

55yo

Età media

Gestione esperta: Il team dirigenziale di GSK è esperto e expertise (durata media dell'incarico 5.7 anni).

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Emma Walmsley	CEO & Director	7.6yrs	UK£12.72m	0.040% £ 25.9m
Julie Brown	CFO & Executive Director	1.3yrs	UK£5.14m	0.0024% £ 1.6m
Jonathan Symonds	Non-Executive Chairman	4.9yrs	UK£765.00k	0.0018% £ 1.2m
Vishal Sikka	Independent Non-Executive Director	2.1yrs	UK£147.00k	0.00026% £ 168.8k
Hal Barron	Non-Executive Director	6.6yrs	UK£356.92k	0.00052% £ 337.7k
Harry Dietz	Independent Non-Executive Director	2.6yrs	UK£207.09k	0.00014% £ 90.9k
Anne Beal	Independent Non-Executive Director	3.3yrs	UK£174.93k	0.00015% £ 97.4k
Wendy Mira Becker	Independent Non-Executive Director	less than a year	UK£32.00k	0.000030% £ 19.5k
Charles Bancroft	Senior Independent Non-Executive Director	4.3yrs	UK£323.00k	0.0012% £ 805.2k
Tsun-Huei Lee	Independent Non-Executive Director	less than a year	Nessun dato	0.000010% £ 6.5k
Elizabeth Anderson	Independent Non-Executive Director	1.9yrs	UK£127.86k	0.000080% £ 51.9k
Jesse Goodman	Independent Non-Executive Director	8.6yrs	UK£173.36k	0.00070% £ 454.6k

2.9yrs

Durata media

62yo

Età media

Consiglio di amministrazione esperto: Il consiglio di amministrazione di GSK non è considerato esperto (durata media del mandato 2.9 anni), il che suggerisce un nuovo consiglio.

GSK Gestione

Gestione criteri di controllo 1/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

Gsk plc Announces Board Committee Changes

We Think Shareholders Are Less Likely To Approve A Large Pay Rise For GSK plc's (LON:GSK) CEO For Now

GSK plc, Annual General Meeting, May 08, 2024

GSK plc Appoints Hal Dietz as Member of Nominations & Corporate Governance Committee, Effective 11 March 2024

CEO & Director exercised options and sold UK£2.3m worth of stock

Recent updates

GSK plc Receives US Food and Drug Administration Breakthrough Therapy Designation for GSK5764227

Gsk plc Announces Zantac (Ranitidine) Litigation Update

GSK plc Announces Zantac (Ranitidine) Litigation Update

GSK (LON:GSK) Is Paying Out A Dividend Of £0.15

Second quarter dividend of UK£0.15 announced

GSK plc Announces US FDA Expands Jemperli (Dostarlimab-Gxly) Plus Chemotherapy Approval to All Adult Patients with Primary Advanced or Recurrent Endometrial Cancer as the First and Only Immuno-Oncology-Based Treatment to Show an Overall Survival Benefit

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

GSK plc Declares Second Interim Dividend for Second Quarter of 2024, Payable on 10 October 2024

GSK plc Announces Blenrep EMA Filing Acceptance

GSK plc Begins Shipping Influenza Vaccine Doses for 2024-25 Season

GSK's Omjjara (Momelotinib) Receives Approval in Japan for Treatment of Myelofibrosis

iTeos Therapeutics, Inc. and GSK Initiate GALAXIES Lung-301 Phase 3 Study, Assessing Belrestotug and Dostarlimab in Previously Unresectable Locally Advanced / Metastatic PD-L1 Selected Non-Small Cell Lung Cancer

GSK plc Announces That the US Food and Drug Administration (FDA) Has Approved Arexvy

GSK plc (LSE:GSK) acquired Elsie Biotechnologies for $50 million.

GSK plc Announces Positive Results from an Interim Analysis of the DREAMM-8 Phase III Head-To-Head Trial Evaluating Belantamab Mafodotin

GSK plc Provides Litigation Update

An unknown buyer intended to acquire 4.2% stake in Haleon plc (LSE:HLN) from GSK plc (LSE:GSK) for £1.2 billion.

GSK Announces Intention to Sell Approximately 385 Million Shares in Haleon

Gsk plc Announces Board Committee Changes

GSK (LON:GSK) Will Pay A Dividend Of £0.15

First quarter dividend of UK£0.15 announced

GSK plc to Report Q2, 2024 Results on Jul 31, 2024

We Think Shareholders Are Less Likely To Approve A Large Pay Rise For GSK plc's (LON:GSK) CEO For Now

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

GSK plc Announces the US Food and Drug Administration Accepted the Supplemental Biologics License Application for Jemperli

These 4 Measures Indicate That GSK (LON:GSK) Is Using Debt Reasonably Well

GSK plc Announces Positive Results from the Pivotal Eagle-1 Phase III Trial for Gepotidacin

GSK plc Announces US Food and Drug Administration Accepts for Review Biologics License Application for its 5-in-1 Meningococcal ABCWY (MenABCWY) Vaccine Candidate

GSK plc, Annual General Meeting, May 08, 2024

GSK plc Appoints Hal Dietz as Member of Nominations & Corporate Governance Committee, Effective 11 March 2024

GSK plc Announces Positive Headline Results from an Interim Analysis of the Dreamm-8 Phase Iii Head-To-Head Trial Evaluating Blenrep (Belantamab Mafodotin)

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

GSK plc Reaches a Confidential Settlement with Boyd/Steenvoord

CEO & Director exercised options and sold UK£2.3m worth of stock

GSK plc (LSE:GSK) completed the acquisition of Aiolos Bio, Inc. from a group of shareholders.

Upcoming dividend of UK£0.16 per share at 3.5% yield

GSK plc Receives US Food and Drug Administration Fast Track Designation for Bepirovirsen in Chronic Hepatitis B

Center for Drug Evaluation Accepts to Review GSK's Regulatory Application for Shingrix for the Prevention of Shingles in at-Risk Adults Aged 18 and over

GSK's (LON:GSK) Solid Earnings Are Supported By Other Strong Factors

Gsk plc Announces Results from an Interim Analysis of The DREAMM-7 Phase III Head-To-Head Trial

GSK plc to Report Q1, 2024 Results on May 01, 2024

Fourth quarter dividend of UK£0.16 announced

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

GSK plc Provides an Update on Zantac (Ranitidine) Litigation

GSK plc Provides Earnings Guidance for the Year 2024

European Medicines Agency Accepts GSK's Arexvy Filing for Adults 50-59 At Risk

Price target increased by 10% to UK£19.22

We Think GSK (LON:GSK) Can Stay On Top Of Its Debt

Analisi delle retribuzioni degli amministratori delegati

AMMINISTRATORE DELEGATO

Mandato

Compensazione

Gruppo dirigente

Durata media

Età media

Membri del Consiglio di amministrazione

Durata media

Età media